Aura Biosciences, Inc. AURA
Updated: 10 Aug 2026
No signal published yet
We already track Aura Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Aura Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Aura Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 1, 2026, Aura Biosciences announced the completion of patient enrollment in its pivotal Phase 3 CoMpass trial evaluating bel-sar for early choroidal melanoma. Topline data from the study are expected in the second half of 2027. The company also appointed Dr. Jeremy Bender to its Board of Directors in July 2026.
What Firelda Watch includes for Aura Biosciences, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Aura Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Aura Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more